Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Matrix Metalloproteise 9 (Gelatise B or 92 kDa Type IV Collagese or 92 kDa Gelatise or MMP9 or EC 3.4.24.35) - Overview
Matrix Metalloproteise 9 (Gelatise B or 92 kDa Type IV Collagese or 92 kDa Gelatise or MMP9 or EC 3.4.24.35) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Matrix Metalloproteise 9 (Gelatise B or 92 kDa Type IV Collagese or 92 kDa Gelatise or MMP9 or EC 3.4.24.35) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Matrix Metalloproteise 9 (Gelatise B or 92 kDa Type IV Collagese or 92 kDa Gelatise or MMP9 or EC 3.4.24.35) - Companies Involved in Therapeutics Development
Aquilus Pharmaceuticals Inc
EA Pharma Co Ltd
Elastomics AB
Gilead Sciences Inc
Iproteos SL
MabTrix Ltd
Pharmahungary Group
Proteris Biotech Inc
Shulov Innovative Science Ltd
Translatiol Sciences Inc
Matrix Metalloproteise 9 (Gelatise B or 92 kDa Type IV Collagese or 92 kDa Gelatise or MMP9 or EC 3.4.24.35) - Drug Profiles
andecaliximab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AQU-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AQU-118 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CALY-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Inhibit Matrix Metalloproteise 9 for Acute Ischemic Stroke - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IPRO-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibody to Inhibit MMP9 for Inflammatory Bowel Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-336 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protearin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombint MMP-9 Replacement for Liver Fibrosis, Pulmory Fibrosis, Peyronies Disease, Dupuytren Contracture and Pancreatic Islet Transplant Rejection - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombint Protein to Target MMP-9 for Wounds - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Matrix Metalloproteise 9 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Carbonic Anhydrases and MMPs for Metastatic Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MMP 2,9 and 13 for Myocardial Infarction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target MMP2 and MMP9 for Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZEP-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Matrix Metalloproteise 9 (Gelatise B or 92 kDa Type IV Collagese or 92 kDa Gelatise or MMP9 or EC 3.4.24.35) - Dormant Products
Matrix Metalloproteise 9 (Gelatise B or 92 kDa Type IV Collagese or 92 kDa Gelatise or MMP9 or EC 3.4.24.35) - Discontinued Products
Matrix Metalloproteise 9 (Gelatise B or 92 kDa Type IV Collagese or 92 kDa Gelatise or MMP9 or EC 3.4.24.35) - Product Development Milestones
Featured News & Press Releases
Nov 07, 2018: California research team publishes promising results from peptide based universal cancer vaccine
Nov 02, 2016: Abze Provides Update on GS-5745
Sep 21, 2016: Gilead Termites Phase 2/3 Study of GS-5745 in Patients With Ulcerative Colitis
May 13, 2015: Abze provides an update on the clinical development of one of the humanized antibodies created using its Composite Human Antibody technology
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Aquilus Pharmaceuticals Inc, H1 2020
Pipeline by EA Pharma Co Ltd, H1 2020
Pipeline by Elastomics AB, H1 2020
Pipeline by Gilead Sciences Inc, H1 2020
Pipeline by Iproteos SL, H1 2020
Pipeline by MabTrix Ltd, H1 2020
Pipeline by Pharmahungary Group, H1 2020
Pipeline by Proteris Biotech Inc, H1 2020
Pipeline by Shulov Innovative Science Ltd, H1 2020
Pipeline by Translational Sciences Inc, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Discontinued Products, H1 2020